Recent Progress in Alzheimer's and Parkinson's Diseases PDF
Preview Recent Progress in Alzheimer's and Parkinson's Diseases
Prelims Revised 31/3/05 2:50 pm Page i Recent Progress in Alzheimer’s and Parkinson’s Diseases Prelims Revised 31/3/05 2:51 pm Page ii Her Majesty Queen Sophia of Spain Prelims Revised 31/3/05 2:51 pm Page iii Recent Progress in Alzheimer’s and Parkinson’s Diseases Edited by Israel Hanin PhD Professor and Chairman Emeritus, Department of Pharmacology and Experimental Therapeutics Loyola University Medical Center Maywood, Illinois, USA Ramón Cacabelos MD PhD DMSci President and Chief Executive Officer EuroEspes, Santa Marta de Babío La Coruña Spain Abraham Fisher PhD Senior Scientist Israel Institute for Biological Research Ness-Ziona Israel LONDON AND NEW YORK Prelims Revised 31/3/05 2:51 pm Page iv © 2005 Taylor & Francis, an imprint of the Taylor & Francis Group First published in the United Kingdom in 2005 by Taylor & Francis, an imprint of the Taylor & Francis Group, 2 Park Square, Milton Park Abingdon, Oxon OX14 4RN, UK Tel.: +44 (0) 20 7017 6000 Fax.: +44 (0) 20 7017 6699 Website: www.tandf.co.uk All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or trans- mitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the publisher or in accordance with the provisions of the Copyright, Designs and Patents Act 1988 or under the terms of any licence permitting limited copying issued by the Copyright Licensing Agency, 90 Tottenham Court Road, London W1P 0LP. Although every effort has been made to ensure that all owners of copyright material have been acknowl- edged in this publication, we would be glad to acknowledge in subsequent reprints or editions any omis- sions brought to our attention. British Library Cataloguing in Publication Data Data available on application Library of Congress Cataloging-in-Publication Data Data available on application ISBN 1-84184-320-2 Distributed in North and South America by Taylor & Francis 2000 NW Corporate Blvd Boca Raton, FL 33431, USA Within Continental USA Tel.: 800 272 7737; Fax.: 800 374 3401 Outside Continental USA Tel.: 561 994 0555; Fax.: 561 361 6018 E-mail: [email protected] Distributed in the rest of the world by Thomson Publishing Services Cheriton House North Way Andover, Hampshire SP10 5BE, UK Tel.: +44 (0) 1264 332424 E-mail: [email protected] Composition by Parthenon Publishing Printed and bound by Antony Rowe Ltd., Chippenham, Wiltshire, UK Prelims Revised 31/3/05 2:51 pm Page v Contents List of Contributors ix Preface xxi 1. Mechanisms of degeneration in Parkinson’s disease 1 B Wolozin, M Frasier, H Snyder, P Choi, N Golts 2. Underlying biochemical and molecular mechanisms of dyskinesia 9 H Reichmann, P Riederer 3. Molecular neuropathology of parkinsonism 19 DW Dickson 4. Familial parkinsonian mutations affect the ability of catecholaminergic neurons to 27 withstand proteasome inhibition MR Cookson 5. Acetylcholinesterase, cholinergic signaling and Parkinson’s disease 33 Y Ben-Shaul, H Bergman, H Soreq 6. Bone marrow stem cells: possible source for cell therapy in Parkinson’s disease 45 YS Levy, S Bulvik, A Burshtein, Y Barhum, E Melamed, D Offen 7. Insulin-like growth factor I and intracellular signal transduction pathways 53 in aging and dementia W-H Zheng, R Quirion 8. The interrelationships between gait and cognitive function 61 N Giladi, PL Sheridan, JM Hausdorff 9. Advances in gene transfer and pharmacological regulation of protein aggregation 69 in the treatment of Alzheimer’s and Parkinson’s diseases P Bar-On, E Rockenstein, M Hashimoto, E Masliah v Prelims Revised 31/3/05 2:51 pm Page vi Recent Progress in Alzheimer’s and Parkinson’s Diseases 10. α- andβ-Synucleins: two parent proteins that display similar anti-apoptotic 81 phenotypes but distinct responses to 6-hydroxydopamine-induced toxicity F Checler, C Alves da Costa 11. Functional genomics and pharmacogenetics in Alzheimer’s disease 89 R Cacabelos, Y Kubota, C Isaza, J Henao, L Fernández-Novoa, VRM Lombardi, L Corzo, V Pichel 12. The genetics of tau and neurodegenerative disease 103 BKraemer, I D’Souza, GD Schellenberg 13. Amyloid plaques and neurofibrillary tangles in a triple transgenic model: qualitative 111 similarities with human Alzheimer’s neuropathology S Oddo, FM LaFerla 14. Apolipoprotein E and Alzheimer’s disease: what has a decade told us? 117 KA Crutcher 15. Comparison of the effects of apolipoprotein E4 on presynaptic and cytoskeletal 127 plasticity following environmental stimulation O Levi, DM Michaelson 16. Cholesterol and the Aβ cascade: pathological implication of apolipoprotein E 133 in Alzheimer’s disease K Yanagisawa 17. Brain inflammation and psychogeriatric diseases 139 H Akiyama, H Uchikado 18. Neuroinflammatory mechanisms are involved in the early steps of the pathological 145 cascade in Alzheimer’s disease P Eikelenboom, JJM Hoozemans, JM Rozemuller, R Veerhuis, WA van Gool 19. Vascular nitric oxide: a key molecule in Alzheimer’s disease pathogenesis 153 JC de la Torre 20. Alzheimer pathology and endoplasmic reticulum stress 161 T Kudo, T Katayama, K Imaizumi, D Kanayama, J Hitomi, M Okochi, M Tohyama, M Takeda 21. Molecular mechanism of amyloid β-peptide-induced impairment of neurotransmission 167 and memory in relation to oxidative stress K Yamada, H-C Kim, T Nabeshima 22. Regulating factors for microglial activation: implication for Alzheimer’s disease and 171 brain damage VRM Lombardi, L Fernández-Novoa, I Etcheverría, S Seoane, R Cacabelos 23. Cerebrospinal fluid phosphorylated tau protein at serine 199 is a useful diagnostic 177 biomarker in Alzheimer’s disease and mild cognitive impairment K Urakami, H Arai, N Itoh, K Ishiguro, H Oono, M Taniguchi, K Wada-Isoe, Y Wakutani, S Kuzuhara, H Sasaki, K Nakashima, K Imahori vi Prelims Revised 31/3/05 2:51 pm Page vii Contents 24. Stem cell strategies for Alzheimer’s disease 183 K Sugaya 25. Can mild cognitive impairment predict Alzheimer’s disease? 191 H Soininen, S Tuomainen, C Pennanen, T Hänninen, M Kivipelto 26. Water quality and cholesterol-induced pathology: differential effects of the M-1 197 muscarinic receptor agonist AF267B on accumulation of Alzheimer-like amyloid β in rabbit brain DL Sparks, J Lochhead, A Fisher, T Martin 27. Lack of effect of certoparin in P301L mutant tau pathology 205 M Walzer, M Hejna, S Lorens, J Lee 28. Heparin-derived oligosaccharides as potential therapeutic agents in senile dementia 211 and stroke Q Ma, I Hanin, U Cornelli, J Lee, O Iqbal, J Fareed 29. Glycosaminoglycans and neuroprotection: effect on cholinergic neurodegeneration 227 B Dudas, M Rose, U Cornelli, L De Ambrosi, M Cornelli, I Hanin 30. Orchestration of the functional subsites in the acetylcholinesterase active center – 235 contribution to catalytic perfection and high reactivity toward specific ligands A Shafferman, D Barak, A Ordentlich, N Ariel, C Kronman, D Kaplan, B Velan 31. Altered glycosylation of acetylcholinesterase in the Alzheimer’s disease brain: 243 involvement of α7 nicotinic acetylcholine receptors DH Small, LR Fodero, J Sáez-Valero 32. Cholinotrophic alterations in individuals with mild cognitive impairment and 249 Alzheimer’s disease EJ Mufson, M Fahnestock, JH Kordower, ST DeKosky 33. Pharmacological properties of TV3326, a cholinesterase and brain selective 257 monoamine oxidase inhibitor for the treatment of dementia co-morbid with depression M Weinstock, MBH Youdim 34. Physostigmine and its analog phenserine have different effects on Alzheimer 261 amyloid-β precursor protein DK Lahiri, GM Alley, MR Farlow, JT Rogers, NH Greig 35. Translation and processing of amyloid precursor protein (APP) by an M1 muscarinic 267 agonist and an acetylcholinesterase inhibitor: the role of APP mRNA5′-untranslated region sequences JT Rogers, NH Greig, DK Lahiri, A Fisher 36. Modulation of Alzheimer’s amyloidosis by statins: possible mechanisms of action 279 S Petanceska, M Pappolla, LM Refolo 37. β-secretase – progress and questions 291 M Citron vii Prelims Revised 31/3/05 2:51 pm Page viii Recent Progress in Alzheimer’s and Parkinson’s Disease 38. Tau phosphorylation and assembly in tauopathies 297 J Avila, M Pérez, A Gómez-Ramos, JJ Lucas, F Hernández 39. Alzheimer’s disease: a true tauopathy fueled by amyloid precursor protein dysfunction 301 A Delacourte 40. Neurofibrillary degeneration: a promising target for the treatment of Alzheimer’s 309 disease and other tauopathies K Iqbal, A del C Alonso, E El-Akkad, C-X Gong, N Haque, S Khatoon, H Tanimukai, I Tsujio, I Grundke-Iqbal 41. Neuropathology and tau 317 KA Jellinger 42. Conformational analysis of tau and tau aggregates by fluorescence spectroscopy 329 M von Bergen, L Li, E-M Mandelkow, E Mandelkow 43. Transglutaminase-catalyzed cross-linking of tau in Alzheimer’s disease and 339 progressive supranuclear palsy NA Muma, RA Halverson 44. The impact of extracellular amyloid-β (Αβ) peptides on cortical neurotransmitters and 347 of intracellular Aβ accumulation on protein expression AC Cuello, KFS Bell, V Echeverria, E Lopez, A Ribeiro-da-Silva, M Szyf 45. Activation of Wntsignaling protects from amyloid-β-peptide neurotoxicity 355 NC Inestrosa, MS Urra, J Scheu, GG Farias, A Fisher, M Bronfman, RA Fuentealba 46. Human prion diseases 363 T Pan, R Li, B-S Wong, S-C Kang, P Gambetti, M-S Sy Index 371 viii Prelims Revised 31/3/05 2:51 pm Page ix List of contributors H AkiyamaMD PhD J AvilaPhD Tokyo Institute of Psychiatry Centro de Biología Molecular “Severo Ochoa” Department of Psychogeriatrics Facultad de Ciencias 2-1-8 Kamikitazawa Campus de Cantoblanco Setagaya-ku Universidad Autónoma de Madrid Tokyo 156-8585 28049 Madrid Japan Spain GM AlleyBS D Barak Department of Psychiatry and Neurology Department of Organic Chemistry Institute of Psychiatric Research Israel Institute for Biological Research Indiana University School of Medicine Ness-Ziona 74100 791 Union Drive, Rm PR-313 Israel Indianapolis, IN 46202-4887 P Bar-On USA Department of Neurosciences C Alves da CostaPhD University of California Institut de Pharmacologie Moléculaire et Cellulaire San Diego UMR6097 CNRS/UNSA La Jolla, CA 92093-0624 660 Route des Lucioles USA 06560 Valbonne Y BarhumMSc France Laboratory of Neuroscience H AraiMD PhD Felsenstein Medical Research Center and Department of Geriatrics Department of Neurology Tohoku University School of Medicine Rabin Medical Center Sendai 980-8578 Beilinson Campus Japan Tel Aviv University Sackler School of Medicine N Ariel Petah-Tikva 49100 Department of Biochemistry and Molecular Genetics Israel Israel Institute for Biological Research Ness-Ziona 74100 Israel ix
Description:The list of books you might like
